Review
BibTex RIS Cite

Kanser ve ayak sağlığı: onkoloji hastalarına özgü podolojik yaklaşımlar

Year 2025, Volume: 8 Issue: 3, 529 - 534, 30.05.2025
https://doi.org/10.32322/jhsm.1626323

Abstract

Kanser, dünya genelinde yüksek mortalite ve morbidite oranlarına sahip karmaşık bir hastalık grubudur. Bu hastalık grubunda kullanılan tedavi yöntemleri, yaşam kalitesini önemli ölçüde etkileyen cilt ve tırnak toksisiteleri, el-ayak sendromu ve periferik nöropati gibi yan etkilere yol açabilmektedir. Podoloji bilimi, bu etkilerin önlenmesi ve yönetilmesi açısından kritik bir rol oynamaktadır. Bu derleme, kanser tedavilerinde sıkça görülen ayak sağlığı sorunlarını, bu sorunların patofizyolojisini ve multidisipliner yaklaşımla sunulabilecek podolojik çözümleri sistematik bir şekilde ele almayı amaçlamaktadır. Ayrıca, Podologlar ve onkoloji uzmanlarının iş birliği ile ayak sağlığının korunmasının tedavi sürecindeki katkıları vurgulanmıştır. Derlemede, kemoterapi, radyoterapi ve immünoterapinin ayak sağlığı üzerindeki etkileri detaylandırılmış ve bu etkilerin yönetimi için uygulamalı öneriler sunulmuştur.

Project Number

None

References

  • Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10. 3322/caac.21834
  • Kayıkçı EE, Can G. The effect of salt-water bath in the management of treatment-related peripheral neuropathy in cancer patients receiving taxane and platinum-based treatment. Explore (NY). 2022;18(3):347-356. doi:10.1016/j.explore.2021.07.002
  • Wan M, Luo X, Wang J, et al. The impact on quality of life from informing diagnosis in patients with cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):618. doi:10.1186/s12885-020-07096-6
  • Tachi T, Teramachi H, Tanaka K, et al. The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients. PLoS One. 2015;10(4):e0124169. doi:10.1371/journal.pone.0124169
  • Hagiwara Y, Shiroiwa T, Shimozuma K, et al. Impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the SELECT BC study. Pharmacoeconomics. 2018;36:215-223. doi:10.1007/s40273-017-0580-7
  • Lacouture ME, Kopsky DJ, Lilker R, et al. Podiatric adverse events and foot care in cancer patients and survivors: awareness, education, and literature review. J Am Podiatr Med Assoc. 2018;108(6):508-516. doi:10. 7547/17-010
  • Palomo-López P, Rodríguez-Sanz D, Becerro-de-Bengoa-Vallejo R, et al. Clinical aspects of foot health and their influence on quality of life among breast cancer survivors: a case-control study. Cancer Manag Res. 2017;9:545-551. doi:10.2147/CMAR.S151343
  • Nádašiová M. Podiatry, podology and pedicure. Int J Health New Technol Soc Work. 2018;13(4):4-10.
  • Gilbar P, Hain A, Peereboom VM. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract. 2009;15(3):143-155. doi:10.1177/ 1078155208100450
  • Saadet ED, Tek I. Evaluation of chemotherapy-induced cutaneous side effects in cancer patients. Int J Dermatol. 2022;61(12):1519-1526. doi:10. 1111/ijd.16361
  • Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. 2011;16(2):228-238. doi:10. 1634/theoncologist.2010-0298
  • Fabbrocini G, Cameli N, Romano MC, et al. Chemotherapy and skin reactions. J Exp Clin Cancer Res. 2012;31(1):50. doi:10.1186/1756-9966-31-50
  • Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009;4(2):107-119. doi:10.1007/s11523-009-0114-0
  • Piraccini BM, Iorizzo M, Antonucci A, Tosti A. Drug-induced nail abnormalities. Expert Opin Drug Saf. 2004;3(1):57-65. doi:10.1517/1474 0338.3.1.57
  • Singal A, Bisherwal K. Melanonychia: etiology, diagnosis, and treatment. Indian Dermatol Online J. 2020;11(1):1-11. doi:10.4103/idoj.IDOJ_167_19
  • Samson P, Curvale C, Iniesta A, Gay A. Managing longitudinal melanonychia. Hand Surg Rehabil. 2024;43S:101526. doi:10.1016/j.hansur.2022.12.007
  • Robert C, Sibaud V, Mateus C, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16(4):e181-e189. doi:10.1016/S1470-2045(14)71133-7
  • Alizadeh N, Mirpour SH, Darjani A, Rafiei R, Rafiei E, Mohammadhoseini M. Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature. Int J Dermatol. 2020;59(7):822-828. doi:10.1111/ijd. 14916
  • Cuervo-Maldonado SI, Álvarez-Rodríguez JC, Cubides CL, et al. Fusariosis in cancer patients: 13 case series report and literature review. Biomedica. 2023;43(Sp. 1):41-56. doi:10.7705/biomedica.6925
  • Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020; 14(1):442. doi:10.4081/oncol.2020.442
  • Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787-794. doi:10.1016/j.jaad.2014.03.019
  • Li Y, Huang W, Zhang L, et al. Evaluation of the preventive effect of regional cooling nursing on hand-foot syndrome caused by doxorubicin hydrochloride liposome. Open J Nurs. 2022;12(11):772-781. doi:10.4236/ojn.2022.1211054
  • Bun S, Yunokawa M, Tamaki Y, et al. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer. Support Care Cancer. 2018;26: 2161-2166. doi:10.1007/s00520-018-4054-z
  • Tofthagen C, Overcash J, Kip K. Falls in persons with chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2012;20(3):583-589. doi:10.1007/s00520-011-1127-7
  • Cathcart-Rake EJ, Hilliker DR, Loprinzi CL. Chemotherapy-induced neuropathy: central resolution of a peripherally perceived problem? Cancer. 2017;123(11):1898-1900. doi:10.1002/cncr.30650
  • Veiga-Seijo R, González-Bartol E, Pérez-Ríos N, Pazos-Couselo M, Romero-Bernárdez D, Seoane-Pillado T. Wellbeing and complementary therapies in breast cancer peripheral neuropathy care: a scoping review focused on foot health. Cancers (Basel). 2023;15(7):2110. doi:10.3390/cancers15072110
  • Čeović R, Kovačec L, Bukvić Mokos Z, Marinović B. Dermatologic adverse events in oncologic therapies. Acta Dermatovenerol Croat. 2022; 30(4):237-249.
  • Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol. 2002;14(2):212-216. doi:10.1097/00001622-200203000-00012

Cancer and foot health: special podologic approaches to oncology patients

Year 2025, Volume: 8 Issue: 3, 529 - 534, 30.05.2025
https://doi.org/10.32322/jhsm.1626323

Abstract

Cancer comprises a heterogeneous group of diseases associated with substantial global mortality and morbidity. Therapeutic modalities for these diseases frequently produce adverse effects-most notably skin and nail toxicities, hand-foot syndrome (HFS; palmar-plantar erythrodysesthesia), and peripheral neuropathy-that can markedly diminish patients’ quality of life. Podiatric care is therefore critical for preventing and mitigating these sequelae. In this review, we systematically examine the foot-related complications of cancer therapy, describe their underlying pathophysiology, and delineate multidisciplinary podiatric interventions. We also highlight the benefits of close collaboration between podiatrists and oncology specialists in maintaining foot health during treatment. Finally, we summarise the specific effects of chemotherapy, radiotherapy, and immunotherapy on the feet and provide evidence-based recommendations for their management.

Ethical Statement

ETHICS COMMITTEE APPROVAL WAS NOT OBTAINED FOR THE REVIEW ARTICLE.

Supporting Institution

None.

Project Number

None

Thanks

None.

References

  • Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10. 3322/caac.21834
  • Kayıkçı EE, Can G. The effect of salt-water bath in the management of treatment-related peripheral neuropathy in cancer patients receiving taxane and platinum-based treatment. Explore (NY). 2022;18(3):347-356. doi:10.1016/j.explore.2021.07.002
  • Wan M, Luo X, Wang J, et al. The impact on quality of life from informing diagnosis in patients with cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):618. doi:10.1186/s12885-020-07096-6
  • Tachi T, Teramachi H, Tanaka K, et al. The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients. PLoS One. 2015;10(4):e0124169. doi:10.1371/journal.pone.0124169
  • Hagiwara Y, Shiroiwa T, Shimozuma K, et al. Impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the SELECT BC study. Pharmacoeconomics. 2018;36:215-223. doi:10.1007/s40273-017-0580-7
  • Lacouture ME, Kopsky DJ, Lilker R, et al. Podiatric adverse events and foot care in cancer patients and survivors: awareness, education, and literature review. J Am Podiatr Med Assoc. 2018;108(6):508-516. doi:10. 7547/17-010
  • Palomo-López P, Rodríguez-Sanz D, Becerro-de-Bengoa-Vallejo R, et al. Clinical aspects of foot health and their influence on quality of life among breast cancer survivors: a case-control study. Cancer Manag Res. 2017;9:545-551. doi:10.2147/CMAR.S151343
  • Nádašiová M. Podiatry, podology and pedicure. Int J Health New Technol Soc Work. 2018;13(4):4-10.
  • Gilbar P, Hain A, Peereboom VM. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract. 2009;15(3):143-155. doi:10.1177/ 1078155208100450
  • Saadet ED, Tek I. Evaluation of chemotherapy-induced cutaneous side effects in cancer patients. Int J Dermatol. 2022;61(12):1519-1526. doi:10. 1111/ijd.16361
  • Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. 2011;16(2):228-238. doi:10. 1634/theoncologist.2010-0298
  • Fabbrocini G, Cameli N, Romano MC, et al. Chemotherapy and skin reactions. J Exp Clin Cancer Res. 2012;31(1):50. doi:10.1186/1756-9966-31-50
  • Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009;4(2):107-119. doi:10.1007/s11523-009-0114-0
  • Piraccini BM, Iorizzo M, Antonucci A, Tosti A. Drug-induced nail abnormalities. Expert Opin Drug Saf. 2004;3(1):57-65. doi:10.1517/1474 0338.3.1.57
  • Singal A, Bisherwal K. Melanonychia: etiology, diagnosis, and treatment. Indian Dermatol Online J. 2020;11(1):1-11. doi:10.4103/idoj.IDOJ_167_19
  • Samson P, Curvale C, Iniesta A, Gay A. Managing longitudinal melanonychia. Hand Surg Rehabil. 2024;43S:101526. doi:10.1016/j.hansur.2022.12.007
  • Robert C, Sibaud V, Mateus C, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16(4):e181-e189. doi:10.1016/S1470-2045(14)71133-7
  • Alizadeh N, Mirpour SH, Darjani A, Rafiei R, Rafiei E, Mohammadhoseini M. Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature. Int J Dermatol. 2020;59(7):822-828. doi:10.1111/ijd. 14916
  • Cuervo-Maldonado SI, Álvarez-Rodríguez JC, Cubides CL, et al. Fusariosis in cancer patients: 13 case series report and literature review. Biomedica. 2023;43(Sp. 1):41-56. doi:10.7705/biomedica.6925
  • Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020; 14(1):442. doi:10.4081/oncol.2020.442
  • Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787-794. doi:10.1016/j.jaad.2014.03.019
  • Li Y, Huang W, Zhang L, et al. Evaluation of the preventive effect of regional cooling nursing on hand-foot syndrome caused by doxorubicin hydrochloride liposome. Open J Nurs. 2022;12(11):772-781. doi:10.4236/ojn.2022.1211054
  • Bun S, Yunokawa M, Tamaki Y, et al. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer. Support Care Cancer. 2018;26: 2161-2166. doi:10.1007/s00520-018-4054-z
  • Tofthagen C, Overcash J, Kip K. Falls in persons with chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2012;20(3):583-589. doi:10.1007/s00520-011-1127-7
  • Cathcart-Rake EJ, Hilliker DR, Loprinzi CL. Chemotherapy-induced neuropathy: central resolution of a peripherally perceived problem? Cancer. 2017;123(11):1898-1900. doi:10.1002/cncr.30650
  • Veiga-Seijo R, González-Bartol E, Pérez-Ríos N, Pazos-Couselo M, Romero-Bernárdez D, Seoane-Pillado T. Wellbeing and complementary therapies in breast cancer peripheral neuropathy care: a scoping review focused on foot health. Cancers (Basel). 2023;15(7):2110. doi:10.3390/cancers15072110
  • Čeović R, Kovačec L, Bukvić Mokos Z, Marinović B. Dermatologic adverse events in oncologic therapies. Acta Dermatovenerol Croat. 2022; 30(4):237-249.
  • Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol. 2002;14(2):212-216. doi:10.1097/00001622-200203000-00012
There are 28 citations in total.

Details

Primary Language English
Subjects Dermatology, Cancer Therapy (Excl. Chemotherapy and Radiation Therapy), Preventative Health Care, Podiatry
Journal Section Review
Authors

Ayşegül Sarpkaya 0000-0002-8479-0235

Fatmaz Zehra Küçük 0000-0002-0343-5291

Project Number None
Publication Date May 30, 2025
Submission Date January 24, 2025
Acceptance Date May 20, 2025
Published in Issue Year 2025 Volume: 8 Issue: 3

Cite

AMA Sarpkaya A, Küçük FZ. Cancer and foot health: special podologic approaches to oncology patients. J Health Sci Med / JHSM. May 2025;8(3):529-534. doi:10.32322/jhsm.1626323

Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].

The Directories (indexes) and Platforms we are included in are at the bottom of the page.

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show







The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.

       images?q=tbn:ANd9GcRB9r6zRLDl0Pz7om2DQkiTQXqDtuq64Eb1Qg&usqp=CAU

500px-WorldCat_logo.svg.png

atifdizini.png

logo_world_of_journals_no_margin.png

images?q=tbn%3AANd9GcTNpvUjQ4Ffc6uQBqMQrqYMR53c7bRqD9rohCINkko0Y1a_hPSn&usqp=CAU

doaj.png  

images?q=tbn:ANd9GcSpOQFsFv3RdX0lIQJC3SwkFIA-CceHin_ujli_JrqBy3A32A_Tx_oMoIZn96EcrpLwTQg&usqp=CAU

ici2.png

asos-index.png

drji.png





The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.

COPE-logo-300x199.jpgimages?q=tbn:ANd9GcQR6_qdgvxMP9owgnYzJ1M6CS_XzR_d7orTjA&usqp=CAU

icmje_1_orig.png

cc.logo.large.png

ncbi.pngimages?q=tbn:ANd9GcRBcJw8ia8S9TI4Fun5vj3HPzEcEKIvF_jtnw&usqp=CAU

ORCID_logo.png

1*mvsP194Golg0Dmo2rjJ-oQ.jpeg


Our Journal using the DergiPark system indexed are;

Ulakbim TR Dizin,  Index Copernicus, ICI World of JournalsDirectory of Research Journals Indexing (DRJI), General Impact FactorASOS Index, OpenAIRE, MIAR,  EuroPub, WorldCat (OCLC)DOAJ,  Türkiye Citation Index, Türk Medline Index, InfoBase Index


Our Journal using the DergiPark system platforms are;

Google, Google Scholar, CrossRef (DOI), ResearchBib, ICJME, COPE, NCBI, ORCID, Creative Commons, Open Access, and etc.


Journal articles are evaluated as "Double-Blind Peer Review". 

Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user.  https//dergipark.org.tr/tr/pub/jhsm/page/9535

Journal charge policy   https://dergipark.org.tr/tr/pub/jhsm/page/10912

Our journal has been indexed in DOAJ as of May 18, 2020.

Our journal has been indexed in TR-Dizin as of March 12, 2021.


17873

Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.